Scandion Oncology: Revision history

20 August 2022

• curprev 17:4917:49, 20 August 2022‎ 95.149.241.133 talk‎ 46,404 bytes +11‎ No edit summary undo Tag: Visual edit: Switched

22 July 2022

• curprev 17:1717:17, 22 July 2022‎ Louis talk contribs‎ 46,393 bytes +57‎ No edit summary undo Tag: Visual edit

22 June 2022

• curprev 21:5621:56, 22 June 2022‎ Edison talk contribs‎ 46,336 bytes +64‎ →‎Drug-resistance mechanisms are commonly reported undo Tag: Visual edit
• curprev 16:2116:21, 22 June 2022‎ Edison talk contribs‎ 46,272 bytes +87‎ No edit summary undo
• curprev 16:1716:17, 22 June 2022‎ Edison talk contribs‎ 46,185 bytes +39‎ No edit summary undo
• curprev 16:1416:14, 22 June 2022‎ Edison talk contribs‎ 46,146 bytes +204‎ →‎Two shots on goal for SCO-101 undo Tag: Visual edit
• curprev 16:1016:10, 22 June 2022‎ Edison talk contribs‎ 45,942 bytes +104‎ →‎Further studies will require fresh capital undo Tag: Visual edit
• curprev 15:0715:07, 22 June 2022‎ Edison talk contribs‎ 45,838 bytes +6,948‎ →‎Summary undo Tag: Visual edit

21 June 2022

• curprev 23:5023:50, 21 June 2022‎ Edison talk contribs‎ 38,890 bytes +38,890‎ Created page with "== Summary == '''Scandion Oncology is a Danish biotechnology company that specialises in developing drugs to reverse chemotherapy resistance. Its lead asset, SCO-101, is being investigated as an add-on therapy to existing treatments in metastatic colorectal cancer (mCRC) and unresectable pancreatic cancer (PC). Management’s clinical programme is spearheaded by the Phase II CORIST study in FOLFIRI-resistant mCRC, from which we expect crucial proof-of-concept results in..." Tag: Visual edit